EMEA-000236-PIP03-11 - paediatric investigation plan

aflibercept

Key facts

• Invented name:
  Eylea
• Active substance:
  aflibercept
• Therapeutic area:
  Ophthalmology
• Decision number:
  P/186/2011
• PIP number:
  EMEA-000236-PIP03-11
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of central retinal vein occlusion
• Route(s) of administration:
  Intravitreal use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  02/08/2011
• Compliance check done:
  No

Decision

P/186/2011: EMA decision of 2 August 2011 on the granting of a product specific waiver for aflibercept (EMEA-000236-PIP03-11)

Adopted Reference Number: EMA/500870/2011